Octreotido Depot Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotido Depot, is a somatostatin analog presented as a depot formulation for injection use. It treats hormone‑secreting tumors and related conditions in adults.

GNH USA supplies Octreotido Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide acetate is a synthetic somatostatin analogue that modulates neuroendocrine pathways involved in hormone‑secreting tumours and related disorders. - Acromegaly: reduces excessive growth hormone secretion and improves clinical symptoms. - Neuroendocrine tumours (NETs): controls tumour‑related flushing and diarrhoea. - Carcinoid syndrome: diminishes flushing, bronchospasm and gastrointestinal ​​prolapse ​​symptoms. - Preventive ​for ​post‑operative ​pancreatic ​fistula ​after ​surgery ​in ​high ​risk ​patients ​who ​under ​go ​pan ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

Octreotide acetate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Gastrointestinal disturbances: nausea, abdominal cramping ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  ​ ​ - Flushing: transient reddening of the skin, especially on the face. - Diarrhoea ​ ​ ​​ ​​ - Headache ​ - Fatigue ​

Serious or Rare Side Effects: - Gallbladder disease: formation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Severe hypoglycaemia ​ - Acute pancreatitis ​ - Anaphylaxis ​ - Cardiac ​ ​ ​  ",